Opus Genetics CEO Magrath George buys $97,600 in inventory

Magrath George, the CEO of Opus Genetics, Inc. (NASDAQ:IRD), lately acquired 100,000 shares of the corporate’s frequent inventory. The acquisition, valued at roughly $97,600, was executed at a weighted common worth of $0.976 per share. The shares have been purchased in a number of transactions, with costs starting from $0.97 to $0.98. The timing seems strategic, because the inventory has gained over 14% previously week, now buying and selling at $1.12. In response to InvestingPro knowledge, the corporate maintains robust liquidity with a present ratio of 6.63, whereas analyst worth targets vary from $8 to $15. Need deeper insights into IRD’s valuation and eight further key metrics? Take a look at InvestingPro for unique evaluation and real-time updates. Following this transaction, George holds a complete of 599,150 shares straight.

In different latest information, Opus Genetics, Inc. has made important strides within the discipline of ophthalmic remedies. The corporate has reached an settlement with the U.S. Meals and Drug Administration for a Section 3 scientific trial of APX3330, a possible therapy for reasonable to extreme non-proliferative diabetic retinopathy (NPDR). This improvement follows the latest merger between Opus Genetics and Ocuphire Pharma, forming a brand new entity centered on inherited retinal illnesses.

The corporate’s pipeline consists of the promising Phentolamine Ophthalmic Answer 0.75%, at present present process Section 3 trials for presbyopia and diminished dim mild imaginative and prescient post-surgery. H.C. Wainwright has assigned a Purchase ranking to Opus Genetics, citing the potential of the corporate’s inherited retinal illness platform and the 2025 catalysts for ongoing innovation.

Moreover, Opus Genetics has reported optimistic outcomes from two pivotal Section 3 scientific trials for its eye therapy RYZUMVI. The corporate additionally initiated the VEGA-3 Section 3 scientific trial for the therapy of presbyopia and the LYNX-2 Section 3 trial for decreased visible acuity beneath low mild situations.

These are among the many latest developments at Opus Genetics because it continues to make progress in its mission to advance remedies for eye situations.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.